Targeting CLEC4E in immunosuppressive tumour-associated macrophages via BET inhibition.
Clinical and translational medicine
Liao M, Long K, Dong L, Li Z, Wang W, Hu R, Zhang Y, Su J, Zhu W, Chen X, Yin M.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2025
Cancer Research
Immunology
Single-Cell Analysis
No items found.
Key Finding
A drug screen identified BET inhibitors targeting CLEC4E, and their mechanisms were further investigated using RNA silencing, Chromatin Immunoprecipitation (ChIP)-seq and luciferase reporter assays. Targeting the BRD4/CEBPβ/CLEC4E axis with BET inhibitors represents a promising therapeutic strategy for reprogramming TAMs and enhancing anti-tumour immunity.
Countstar Connection
Countstar Rigel S3 served as the instrument for cell-count assessment in the study's cell samples before single-cell analysis in the 2025 Clinical and translational medicine study.
